Company Overview
Snapshot
Founded in January 2023 by Karny Ilan, Gal Yanuka, and Shani Klein, Feminai operates with 1–10 employees. The company has raised $6M across two funding rounds from 5 investors. In January 2026, Feminai secured a Seed round led by Vertex Ventures Israel.
Business overview
Feminai is dedicated to providing efficient and safe solutions for early breast cancer detection. The company's core offering is a home breast cancer screening device, complemented by a personalized AI-based medical screening plan. Operating within the Health Tech & Life Sciences sector, Feminai serves the diagnostics devices market, leveraging artificial intelligence to enhance women's health.
Strategic signal
In January 2026, Feminai successfully raised $6M in Seed funding, a significant validation of its AI-powered at-home breast cancer screening technology. This capital infusion, led by Vertex Ventures Israel, signals strong investor confidence in Feminai's innovative approach to femtech and its potential to disrupt traditional breast cancer diagnostics, indicating a clear trajectory towards product development and market expansion.
Log in to access full profile ›Company Intelligence Q&A
- What is Feminai's primary focus?
- Feminai focuses on developing efficient and safe solutions for early breast cancer detection, primarily through an at-home screening device combined with an AI-based medical screening plan.
- What was Feminai's most recent funding event?
- In January 2026, Feminai raised $6M in a Seed funding round. Vertex Ventures Israel led this round, with participation from Fusion Fund.
- Has Feminai received any grants?
- In October 2025, Feminai secured a grant from the Israel Innovation Authority.
- What technology does Feminai utilize?
- Feminai leverages artificial intelligence to power its personalized medical screening plans for breast cancer detection.